Tukysa (tucatinib) combined with Herceptin (trastuzumab) and Perjeta (pertuzumab) extended progression-free survival as a frontline maintenance approach compared with placebo plus Herceptin and ...

Giredestrant significantly improved IDFS over SOC endocrine therapy, reducing the risk of invasive disease recurrence or ...

Trodelvy did not show statistically significant PFS improvement over chemotherapy in hormone-receptor-positive/HER2-negative breast cancer post-endocrine therapy. Investigator-assessed PFS showed a ...

In a recent interview with CURE, Dr. Kai Tsao broke down current treatment advancements for patients with prostate cancer.

“In our real-world experience, [Yescarta] in relapsed or refractory follicular lymphoma showed durable responses and a ...

Emmy-winning journalist and author Suleika Jaouad recently delivered the keynote address at the inaugural Blood Cancer Heroes celebration. The event, held in partnership with Bloo ...

Standard-of-care treatment with Janus kinase inhibitor monotherapy improves splenomegaly and symptom burden but provides ...

Epkinly combined with GemOx achieved durable remissions in relapsed/refractory DLBCL, addressing unmet needs in second-line ...

Emphasis on accessible, low-toxicity treatments, including oral therapies, to reduce financial burden and improve patient ...

Orlowski serves as chairman, Ad Interim, and director of Myeloma in the Departments of Lymphoma/Myeloma and Experimental ...

Accurate information about Lynch syndrome is essential. As more people discuss hereditary cancer online, misinformation ...

The oncologist's innovative thinking and deep knowledge provided hope and improved the patient's quality of life. I’ve lived ...